Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of D-Eflornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ARG1 | P05089 | 3/20 | 0.61 |
| ▸ | ARG2 | P78540 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine, (S)- SCHEMBL6779172 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL1322403 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL3022583 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL6779173 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL6779168 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL5051665 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4510 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL1397750 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4809264 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL3238104 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115531555-B | Application of mannose-modified nanoparticles in preparation of medicines for treating osteosarcoma | 上海市第一人民医院 | 2024-02-09 | — | — | CN | disclosed |
| CN-115531555-A | Application of mannose-modified nanoparticles in preparation of drug for treating osteosarcoma | 上海市第一人民医院 | 2022-12-30 | — | — | CN | disclosed |
| CN-113072456-B | Chiral alpha-difluoromethyl amino acid compound and preparation method thereof | 中国科学技术大学 | 2022-04-19 | — | — | CN | disclosed |
| CN-112691120-B | Application of bivalent manganese in preparation of immune enhancement medicine or anti-tumor medicine | 北京大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-114126608-A | Use of immunomodulators to improve nerve regeneration | 得克萨斯州大学系统董事会 | 2022-03-01 | — | — | CN | disclosed |
| CN-113072456-A | Chiral alpha-difluoromethyl amino acid compound and preparation method thereof | 中国科学技术大学 | 2021-07-06 | — | — | CN | disclosed |
| CN-112691120-A | Application of bivalent manganese in preparation of immune enhancement medicine or anti-tumor medicine | 北京大学 | 2021-04-23 | — | — | CN | disclosed |
| CN-105378084-B | Methods and compositions for treating cancer | 瓦尔希伯伦私人肿瘤研究基金会 | 2019-07-05 | — | — | CN | disclosed |
| CN-108601789-A | Tetracyclic quinolone analog combination therapies for treating cancer | 生华生物科技股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2015-07-23 | — | — | US | disclosed |
| US-9062094-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2015-06-23 | — | — | US | disclosed |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| EP-1278537-A2 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY REGULATING ARGINASE I AND POLYAMINE SYNTHESIS | The Research Foundation of the City University of New York (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001085981-A2 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY REGULATING ARGINASE I AND POLYAMINE SYNTHESIS | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | ODC1 820/4885BLM 3105/4885LMNA 1767/4885 |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | ODC1 820/4885BLM 3105/4885LMNA 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.